Qualigen Therapeutics Inc Stock Price, News & Analysis

Qualigen Therapeutics has presented promising data at the AACR Special Conference on RAS, highlighting its novel small molecules targeting RAS in pancreatic and breast cancer models. The studies demonstrated significant anti-RAS activity, showing compounds that bind specifically to certain KRAS mutations, thereby inhibiting cancer cell growth. Chief Medical Officer Tariq Arshad emphasized the potential of these RAS-targeted compounds to improve therapeutic outcomes, particularly for cancers with high relapse rates. The RAS oncogene is implicated in a substantial portion of various cancers, presenting a significant medical need.

Qualigen Therapeutics published significant findings in the journal Molecules, demonstrating that their lead compound QN-302 exhibits strong anti-tumor activity against pancreatic cancer cell lines. The study reveals QN-302 downregulates the S100P gene, associated with several cancers, suggesting its potential as a biomarker for treatment response in pancreatic cancer. The Chief Medical Officer emphasized that this publication reinforces the compound's therapeutic prospects. Pancreatic cancer remains a major health challenge, and Qualigen is advancing QN-302 towards IND application submission in the near future.

Qualigen Therapeutics (Nasdaq: QLGN) provided an update on its progress in 2022, highlighting significant achievements amidst macroeconomic challenges. The company is advancing its lead program, QN-302, a cancer treatment with Orphan Drug Designation for pancreatic cancer, aiming to file an IND application in the first half of 2023. Qualigen also emphasizes ongoing RAS discovery efforts, therapeutic partnerships, and funding strategies. Additionally, QN-247 shows promise in preclinical studies for Triple Negative Breast Cancer, while a focus on NanoSynex aims to enhance rapid antibiotic testing. Austerity measures have been implemented to extend cash runway through 2023.

Qualigen Therapeutics (Nasdaq: QLGN) has initiated Good Laboratory Practice (GLP) toxicology studies for its lead oncology program QN-302, a transcription inhibitor targeting G4-expressing solid tumors like pancreatic cancer. Conducted by WuXi AppTec, these studies are essential for the IND submission expected in H1 2023. Successful completion will allow QN-302 to progress to human clinical trials, addressing a critical need in cancer therapy. The Company emphasizes its commitment to patient's safety and advancement of effective treatments amidst the challenges in cancer care.

Qualigen Therapeutics has promoted Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications, effective January 23, 2023. Mr. Abugan boasts over two decades of experience in the medical diagnostics field and has played a significant role in the commercialization of various Qualigen FastPack^® products. His leadership roles have spanned investor relations, marketing, and technical support. CEO Michael Poirier expressed confidence in Mr. Abugan's future contributions, highlighting the company's aim to enhance its diagnostics business.

Qualigen focuses on developing cancer treatments and has an established diagnostics business.

Qualigen Therapeutics announced that the FDA has granted Orphan Drug Designation (ODD) to its lead drug candidate QN-302 for treating pancreatic cancer. This designation provides several advantages, including seven-year marketing exclusivity and potential tax credits. In 2019, approximately 89,248 people in the U.S. were estimated to have pancreatic cancer, qualifying it for ODD.

Qualigen aims to submit an IND application in the first half of 2023 for a Phase I clinical trial. The company is focused on developing treatments for rare cancers and maintaining its diagnostic products.

Qualigen Therapeutics (Nasdaq: QLGN) provided an update on its subsidiary, NanoSynex, highlighting progress made in 2022 and objectives for 2023. Key achievements include a majority investment transaction, development of a rapid Antimicrobial Susceptibility Test (AST), and successful pilot studies. Looking ahead, NanoSynex aims to secure CE approval, ISO certification, and conduct final clinical studies for the AST, which could significantly enhance infectious disease diagnostics, potentially saving lives and reducing healthcare costs.

Qualigen Therapeutics, Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company received notice from Nasdaq confirming that its common stock has maintained a closing bid price of at least $1.00 per share for 10 consecutive business days. This compliance resolves previous concerns related to its listing on The Nasdaq Capital Market. Qualigen focuses on developing cancer treatments and diagnostics, with investigational compounds like QN-302 and QN-247 targeted at various cancers.

Qualigen Therapeutics (Nasdaq: QLGN) has announced that it received FDA feedback following a pre-Investigational New Drug interaction for its QN-302 compound, aimed at treating advanced solid tumors. This guidance will aid in the preparation of their IND application, expected to be submitted in the first half of 2023. CEO Michael Poirier emphasized the importance of FDA input and collaboration with their Scientific Advisory Board as they advance QN-302 towards clinical trials.